Navigation Links
KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
Date:10/23/2013

NORTH LIBERTY, Iowa, Oct. 23, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has formed a Physician Advisory Council and named renowned pain specialists, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD, as its co-chairs.

In leading KemPharm's Physician Advisory Council, Drs. Gudin and Nalamachu will publicly advocate on behalf of medical professionals, patients and the broader pharmaceutical industry on the need for "intelligent pain therapeutic development" and the value of prodrugs for limiting the abuse-potential and constipation-related side effect of opioid-based medications.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "There continues to be significant interest across the pharmaceutical and pain management industries, as well as the general public, in developing better ways to treat and manage pain.  Teaming with Drs. Gudin and Nalamachu, we have launched our Physician Advisory Council to bring attention to the need for 'intelligent pain therapies' that not only effectively manage the symptoms of pain, but also benefit patients by addressing two critical issues with current opioid-based pain medications – abuse and constipation.  As public advocates, Drs. Gudin and Nalamachu will serve as resources for medical professionals, patients and the pharmaceutical industry with regard to the potential that prodrug-based pain therapeutics provide in limiting these side-effects."

Dr. Jeffrey Gudin is Co-Director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine.  He is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.  His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.

Dr. Gudin received his medical degree from Albany Medical College in Albany, NY.  Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, NJ, he completed a residency in anesthesiology at Yale University School of Medicine.  He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

Dr. Srinivas Nalamachu is President and Medical Director of the International Clinical Research Institute Inc. and Co-Director of the Pain Management Institute in Overland Park, KS.  In addition, Dr. Nalamachu is Clinical Assistant Professor in the Department of Rehabilitation Medicine at Kansas University Medical Center in Kansas City, KS and Clinical Assistant Professor in the Department of Internal Medicine at Kansas City University of Medicine and Biosciences in Kansas City, MO.  Certified by the American Board of Physical Medicine and Rehabilitation, Dr. Nalamachu is a member of the American Academy of Pain Management, American Pain Society, American Association of Electrodiagnostic Medicine and the International Association for Study of Pain.  In addition, he is on the editorial board of Pain Clinician.  His is the principal investigator in numerous studies involving breakthrough, chronic pain, low back pain, and neuropathic pain.  Dr. Nalamachu completed his medical education and mandatory internship from Kakatiya Medical College Teaching Hospitals, Warangal, India.

About KemPharm
KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

www.kempharm.comFor KemPharm, Inc:

Media / Investor Contacts:Christal Mickle

Jason Rando / Claire Sojda 319-665-2575

Tiberend Strategic Advisors, Inc.info@kempharm.com

212.827.0020jrando@tiberend.comcsojda@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
2. KemPharms KP201 to be Featured at PAINWeek 2013
3. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
4. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
5. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
6. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
7. Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013
8. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
9. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
10. Safety Net Clinic and Hospital User Group Forms to Collaborate on 340B Drug Program Best Practices and Transparency Initiatives
11. Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):